Clinical Trial Update: Phase II Trial to Evaluate the Efficacy and Safety of HM61713 as the 1st-line NSCLC Anticancer Therapy [Phase 2]

View source ↗

Summary

A Phase II clinical trial update reports the efficacy and safety of HM61713 as first-line therapy for non-small cell lung cancer (NSCLC). The study status indic…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• HM61713

Snippet

Sponsor: Hanmi Pharmaceutical Company Limited | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: COMPLETED